Emerging role of radiolabeled nanoparticles as an effective diagnostic technique

Barros, André Luís Branco de; Tsourkas, Andrew; Saboury, Babak; Cardoso, Valbert Nascimento; Alavi, Abass

doi:10.1186/2191-219x-2-39

Cited by 130 publications

(93 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cancer treatments require precise spatial identification of tumors. Molecular imaging using SPECT or PET are efficacious imaging modalities for the identification of cancer-specific agents (1). Several radiolabeled targeting agents, including small molecules, peptides, proteins, and antibodies and antibody fragments, have been used in noninvasive imaging and specific detection of tumors.…”

mentioning

confidence: 99%

Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers

et al. 2016

View full text Add to dashboard Cite

Cancer-specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity, and enhanced diffusion into tissues. Glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is overexpressed in various cancers. In this study, we evaluated GIRLRG peptide that specifically targets GRP78 for cancer-specific binding (in vitro) and noninvasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface plasmon resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549), and glioma (D54) tumors. Nano-SPECT/CT imaging of the mice was performed 48 and 72 h after injection with 111 In-labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h after injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with an affinity constant of 2.16 · 10 −3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal, and glioma cells. SPECT imaging revealed that 111 In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung, and brain tumors. Post-SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.

show abstract

mentioning

confidence: 99%

Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Different types of nanoparticles can be used for different imaging techniques: for example, superparamagnetic iron oxide (SPIO) nanoparticles for MRI [48], gold nanoparticles for computed tomography [49], QDs for near-infrared (NIR) fluorescence imaging [50] and radiolabeled nanoparticles for positron emission tomography [51]. However, important parameters like nanoparticle size and surface properties need to be optimized in accordance with the planned treatment.…”

Section: Importance Of Oligonucleotide-based Theranostics In Cancer Tmentioning

confidence: 99%

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Shahbazi

Özpolat

Ulubayram

2016

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Theranostic approaches, combining the functionality of both therapy and imaging, have shown potential in cancer nanomedicine. Oligonucleotides such as small interfering RNA and microRNA, which are powerful therapeutic agents, have been effectively employed in theranostic systems against various cancers. Nanoparticles are used to deliver oligonucleotides into tumors by passive or active targeting while protecting the oligonucleotides from nucleases in the extracellular environment. The use of quantum dots, iron oxide nanoparticles and gold nanoparticles and tagging with contrast agents, like fluorescent dyes, optical or magnetic agents and various radioisotopes, has facilitated early detection of tumors and evaluation of therapeutic efficacy. In this article, we review the advantages of theranostic applications in cancer therapy and imaging, with special attention to oligonucleotide-based therapeutics.

show abstract

“…If the degradation of radiolabeled nanoparticles occurs in vivo before they reach the target, nuclear imaging might yield incorrect information regarding the in vivo distribution of nanoparticles (80). To clarify these issues, distribution and excretion of radioisotopes themselves or the radioisotope-chelator complex should be studied simultaneously with radiolabeled nanoparticles in preclinical models (5,81). Figure 2 summarizes the pitfalls of interpretation of the distribution of systemically administered radiolabeled nanoparticles using radioactivity detection.…”

Section: Issues Of In Vivo Behavior Investigated By Radionanomedicinementioning

confidence: 99%

Translational radionanomedicine: a clinical perspective

Choi¹,

Lee²,

Hwang³

et al. 2016

European Journal of Nanomedicine

View full text Add to dashboard Cite

Many nanomaterials were developed for the anticipated in vivo theranostic use exploiting their unique characteristics as a multifunctional platform. Nevertheless, only a few nanomaterials are under investigation for human use, most of which have not entered clinical trials yet. Radionanomedicine, a convergent discipline of radiotracer technology and use of nanomaterials in vivo, can facilitate clinical nanomedicine because of its advantages of radionuclide imaging and internal radiation therapy. In this review, we focuse on how radionanomedicine would impact profoundly on clinical translation of nanomaterial theranostics. Up-to-date advances and future challenges are critically reviewed regarding the issues of how to radiolabel and engineer radionanomaterials, in vivo behavior tracing of radionanomaterials and then the desired clinical radiation dosimetry. Radiolabeled extracellular vesicles were further discussed as endogenous nanomaterials radiolabeled for possible clinical use.

show abstract

Emerging role of radiolabeled nanoparticles as an effective diagnostic technique

Cited by 130 publications

References 150 publications

Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers

Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers

Oligonucleotide-Based Theranostic Nanoparticles in Cancer Therapy

Translational radionanomedicine: a clinical perspective

Contact Info

Product

Resources

About